Volume 32, Number 1—January 2026
Dispatch
Sphingobacterium hotanense Infections in Immunocompromised Patients, United States
Khalid Abu-Zeinah
, Benjamin D. Lueck, Shane A. Fuentes, Emily Puumala, and Omar M. Abu Saleh
, Benjamin D. Lueck, Shane A. Fuentes, Emily Puumala, and Omar M. Abu Saleh
Table
Antimicrobial susceptibility profile of isolates from blood cultures of 2 patients in report of Sphingobacterium hotanense infection in immunocompromised patients, Minnesota, USA
| Antimicrobial drug | MIC, µg/mL | Susceptibility |
|---|---|---|
| Amikacin | >32 | Resistant |
| Aztreonam | 16 | Intermediate |
| Cefepime | <2 | Susceptible |
| Ceftazidime | <4 | Susceptible |
| Ciprofloxacin | <0.25 | Susceptible |
| Gentamicin | >8 | Resistant |
| Levofloxacin | <0.5 | Susceptible |
| Meropenem | <0.12 | Susceptible |
| Piperacillin/tazobactam | <8/4 | Susceptible |
| Tobramycin | >8 | Resistant |
| Trimethoprim/sulfamethoxazole | <0.5/9.5 | Susceptible |
Page created: December 06, 2025
Page updated: January 29, 2026
Page reviewed: January 29, 2026
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.